Journal of controlled release : official journal of the Controlled Release SocietyPrecision MedicinePeptide SynthasesViolaSingle-Domain AntibodiesRadiopharmaceuticals
VyPAL2 peptide asparaginyl ligase enables versatile workflows for radiolabeling single-domain antibody-based theranostics.
Sofie Declercq, Wei Min Chen, Abbas El Sahili, Arthur Lamouroux, Ilyana Gonzales, Charlotte Martin, Steven Ballet, Vicky Caveliers, Nick Devoogdt, Julien Lescar, Jessica Bridoux
Published: 202510.1016/j.jconrel.2025.114361
Abstract
The growing need for protein-based theranostics calls for precise, efficient conjugation strategies. Here, we report the first application of VyPAL2 - one of the fastest known peptide ligases - for site-specific radiolabeling of single-domain antibod…
Preview only. Read the full abstract at the source